Compare MIRM & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | FICO |
|---|---|---|
| Founded | 2018 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 41.2B |
| IPO Year | 2019 | 1987 |
| Metric | MIRM | FICO |
|---|---|---|
| Price | $78.54 | $1,747.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $92.45 | ★ $1,999.83 |
| AVG Volume (30 Days) | ★ 831.6K | 185.3K |
| Earning Date | 11-04-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.78 |
| EPS | N/A | ★ 26.54 |
| Revenue | $471,794,000.00 | ★ $1,990,869,000.00 |
| Revenue This Year | $53.78 | $24.52 |
| Revenue Next Year | $19.91 | $16.94 |
| P/E Ratio | ★ N/A | $66.76 |
| Revenue Growth | ★ 53.66 | 15.91 |
| 52 Week Low | $36.88 | $1,300.00 |
| 52 Week High | $82.58 | $2,217.60 |
| Indicator | MIRM | FICO |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 48.82 |
| Support Level | $77.99 | $1,701.49 |
| Resistance Level | $82.58 | $1,779.01 |
| Average True Range (ATR) | 3.27 | 43.89 |
| MACD | 1.22 | -6.47 |
| Stochastic Oscillator | 79.12 | 29.20 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.